

NSTE-ACS			
Antiplatelet therapy			
	ASA	I	C
	Clopidogrel (with 600 mg loading dose as soon as possible)	I	C
	Clopidogrel (for 9–12 months after PCI)	I	B
	Prasugrel ^d	IIa	B
	Ticagrelor ^d	I	B
	+ GPIIb–IIIa antagonists (in patients with evidence of high intracoronary thrombus burden)		
	Abciximab (with DAPT)	I	B
	Tirofiban, Eptifibatide	IIa	B
	Upstream GPIIb–IIIa antagonists	III	B
Anticoagulation			
Very high-risk of ischaemia ^e	UFH (+GPIIb–IIIa antagonists) or Bivalirudin (monotherapy)	I	C
Medium-to-high-risk of ischaemia ^e	UFH	I	C
	Bivalirudin	I	B
	Fondaparinux	I	B
	Enoxaparin	IIa	B
Low-risk of ischaemia ^d	Fondaparinux	I	B
	Enoxaparin	IIa	B
STEMI			
Antiplatelet therapy			
	ASA	I	B
	Clopidogrel ^f (with 600 mg loading dose as soon as possible)	I	C
	Prasugrel ^d	I	B
	Ticagrelor ^d	I	B
	+ GPIIb–IIIa antagonists (in patients with evidence of high intracoronary thrombus burden)		
	Abciximab	IIa	A
	Eptifibatide	IIa	B
	Tirofiban	IIb	B
	Upstream GPIIb–IIIa antagonists	III	B
Anticoagulation			
	Bivalirudin (monotherapy)	I	B
	UFH	I	C
	Fondaparinux	III	B